Background Despite advances in cancer care and detection. >65% of patients with squamous cell cancer of the head and neck (HNSCC) will develop recurrent and/or metastatic disease. The prognosis for these patients is poor with a 5-year overall survival of 39%. Recent treatment advances in immunotherapy. https://powerlands.shop/product-category/solar-panels/